Article
Immunology
Donald Hurley, Carl Griffin, Mariano Young, Daniel A. Scott, Michael W. Pride, Ingrid L. Scully, John Ginis, Joseph Severs, Kathrin U. Jansen, William C. Gruber, Wendy Watson
Summary: This study evaluated the safety and immunogenicity of a 20-valent PCV in adults aged 60 to 64 without prior pneumococcal vaccination. Results showed that PCV20 was well tolerated and elicited robust immune responses against all serotypes in this age group, demonstrating its potential to expand pneumococcal disease protection.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Kevin Cannon, Charles Elder, Mariano Young, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William C. Gruber, Wendy Watson
Summary: The study demonstrated that PCV20 is well tolerated and immunogenic in adults over 65 years of age with a history of different pneumococcal vaccine regimens, showing robust immune responses to the 20 vaccine serotypes a month after vaccination.
Article
Immunology
Brandon Essink, Charu Sabharwal, Kevin Cannon, Robert Frenck, Himal Lal, Xia Xu, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Michael W. Pride, Ingrid L. Scully, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson
Summary: The 20-valent pneumococcal conjugate vaccine (PCV20) has shown to be safe and well tolerated, with immunogenicity comparable to that of the 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide vaccine. PCV20 is expected to provide expanded protection against pneumococcal disease in adults.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Immunology
Kevin Cannon, Jose F. Cardona, Kari Yacisin, Allison Thompson, Todd J. Belanger, Dung-Yang Lee, Yahong Peng, Lisa Moyer, John Ginis, William C. Gruber, Daniel A. Scott, Wendy Watson
Summary: This study evaluated the coadministration of PCV20 and QIV and found that the immune responses and safety profile of the coadministration group were comparable to those of the separate administration group, supporting the use of PCV20 and QIV together.
Article
Immunology
Nicola P. Klein, Paula Peyrani, Kari Yacisin, Nicole Caldwell, Xia Xu, Ingrid L. Scully, Daniel A. Scott, Kathrin U. Jansen, William C. Gruber, Wendy Watson
Summary: The three different lots of PCV20 demonstrated robust and consistent immunogenicity, with safety and tolerability comparable to PCV13.
Article
Immunology
Lassane Kabore, Tolulope Adebanjo, Berthe Marie Njanpop-Lafourcade, Soumeya Ouangraoua, Felix T. Tarbangdo, Bertrand Meda, Srinivasan Velusamy, Brice Bicaba, Flavien Ake, Lesley McGee, Seydou Yaro, Edouard Betsem, Alain Gervaix, Bradford D. Gessner, Cynthia G. Whitney, Jennifer C. Moisi, Chris A. Van Beneden
Summary: Within 3 years of PCV13 implementation in Burkina Faso, substantial reductions in the percentage of pneumococcal carriers with a vaccine-type were documented among children under 5 years old, but not among individuals aged 5 years and above. More time, a change in the PCV13 schedule, or both, may be needed to better control pneumococcal carriage in this setting.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Immunology
Stephanie Curry, Robin M. Kaufhold, Morgan A. Monslow, Yuhua Zhang, Debra McGuinness, Ellie Kim, Denise K. Nawrocki, Patrick M. McHugh, Marie L. Briggs, William J. Smith, Jian He, Joseph G. Joyce, Julie M. Skinner
Summary: Despite the effectiveness of pneumococcal conjugate vaccines, residual disease from non-vaccine serotypes remains a global concern. V116, a 21-valent pneumococcal conjugate vaccine, has been developed to address this issue and has shown immunogenicity and cross-reactive functional antibodies in preclinical animal studies. V116 also demonstrated significant protection against a novel serotype not included in currently licensed vaccines.
Article
Biotechnology & Applied Microbiology
Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J. Belanger, Bradford D. Gessner, Luis Jodar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson
Summary: The aim of this study was to investigate the immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adults with chronic medical conditions or smoking. The results showed that PCV20 induced robust immune responses to all 20 vaccine serotypes in participants with increased risk of serious pneumococcal disease.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Health Care Sciences & Services
Christopher C. Blyth, Kathryn J. Britton, Cattram D. Nguyen, Joycelyn Sapura, John Kave, Birunu Nivio, Jocelyn Chan, Catherine Satzke, Rebecca Ford, Wendy Kirarock, Deborah Lehmann, William Pomat, Fiona M. Russell
Summary: This study evaluates the effectiveness of the 13-valent pneumococcal conjugate vaccine (13vPCV) in reducing hypoxic pneumonia and hospitalization in children in Eastern Highlands Province, Papua New Guinea (PNG).
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2022)
Article
Immunology
Jeff Fairman, Paresh Agarwal, Sandrine Barbanel, Christopher Behrens, Aym Berges, John Burky, Peter Davey, Phil Fernsten, Chris Grainger, Sherry Guo, Sam Iki, Mark Iverson, Martin Kane, Neeraj Kapoor, Olivier Marcq, Thi-Sau Migone, Paul Sauer, James Wassil
Summary: This study successfully developed a 24-valent PCV using a proprietary cell-free protein synthesis platform, which showed promising immunogenicity with conjugate-like immune responses to all 24 serotypes. The novel technology has the potential to improve serotype coverage compared to traditional PCVs.
Article
Immunology
Ravinder Kaur, Minh Pham, Karl O. A. Yu, Michael E. Pichichero
Summary: The study found that antibiotic susceptibility of Streptococcus pneumoniae strains isolated from children improved initially after the introduction of PCV13, but began to decrease from 2013 onwards due to the emergence of new serotypes not included in PCV13. These new strains exhibit reduced susceptibility to multiple commonly used antibiotics, compared to the pre-PCV13 era.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Erika Kurihara, Kenichi Takeshita, Saori Tanaka, Noriko Takeuchi, Misako Ohkusu, Haruka Hishiki, Naruhiko Ishiwada
Summary: We conducted a study of 34 cases of pediatric pneumococcal meningitis reported after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Japan. Our results revealed that non-PCV13 serotypes were the main cause of pneumococcal meningitis in children, and all cases with sequelae and death were caused by non-PCV13 serotypes. Furthermore, all penicillin-resistant Streptococcus pneumoniae strains (26.5%; 9/34) belonged to non-PCV13 serotypes. We also analyzed the antimicrobial susceptibilities of isolated S. pneumoniae strains to glycopeptides, linezolid, and daptomycin. All tested strains were susceptible to vancomycin, teicoplanin, linezolid, and daptomycin, with daptomycin showing the best outcome. Pneumococcal meningitis in children remains an ongoing challenge, and monitoring the serotype and antimicrobial susceptibility of strains is crucial for informing treatment strategies.
MICROBIOLOGY SPECTRUM
(2022)
Review
Immunology
Ninecia R. Scott, Beth Mann, Elaine I. Tuomanen, Carlos J. Orihuela
Summary: Streptococcus pneumoniae is a dangerous bacterial pathogen that causes serious diseases, and although current vaccines have limitations in controlling it completely, it is necessary to improve vaccine strategies to enhance protection.
Article
Immunology
Liping Huang, Matt Wasserman, Lindsay Grant, Raymond Farkouh, Vincenza Snow, Adriano Arguedas, Erica Chilson, Reiko Sato, Johnna Perdrizet
Summary: The addition of pneumococcal conjugate vaccines (PCVs) to the US national immunization program has significantly reduced the incidence, mortality, and economic burden of pneumococcal disease (PD) caused by specific serotypes. However, there is still a clinical and economic burden due to PD caused by serotypes not included in the current PCV formulation. The recent approval of 15-valent and 20-valent PCVs in the US provides additional serotype coverage and has the potential to address this unmet need and reduce the burden of PD.
Article
Immunology
Kristina L. Bajema, Ryan Gierke, Monica M. Farley, William Schaffner, Ann Thomas, Arthur L. Reingold, Lee H. Harrison, Ruth Lynfield, Kari E. Burzlaff, Susan Petit, Meghan Barnes, Salina Torres, Paula M. Snippes Vagnone, Bernard Beall, Tamara Pilishvili
Summary: The incidence of antibiotic-nonsusceptible invasive pneumococcal disease (NS-IPD) has decreased in the United States after the introduction of 7- and 13-valent pneumococcal conjugate vaccines (PCVs). However, there has been an increase in nonvaccine type NS-IPD, particularly among older adults. The use of higher valency PCVs containing the common nonsusceptible serotypes could help further reduce NS-IPD.
JOURNAL OF INFECTIOUS DISEASES
(2022)